While better tolerated than chemotherapy, daraxon-rasib's unique toxicity profile (rash, stomatitis) requires a clinical management shift. Oncologists must proactively use strategies like prophylactic antibiotics, a departure from managing typical chemotherapy-induced myelosuppression.

Patient adherence to prophylactic steroid mouthwash is the critical factor in preventing severe stomatitis from datopotamab. Clinicians find that the most severe cases occur in patients who stop the rinse prematurely because they feel fine, highlighting the need for firm and continuous patient education on this non-negotiable preventive measure.

To manage the common side effect of stomatitis from datopotamab deruxtecan (Dato-DXd), a preemptive strategy is effective. Prescribing steroid mouthwash and advising patients to use ice chips during infusion can reduce the severity and incidence of this toxicity.

Nausea with TDXD is severe enough that the drug is now considered highly emetogenic. The standard of care is a prophylactic three-drug antiemetic regimen (NK1 antagonist, 5HT3 antagonist, and dexamethasone). Waiting for nausea to occur before treating is a clinical error; prevention is paramount.

When using the AKT inhibitor capivasertib, preventing rash is more effective than treating it. A recommended strategy for physicians unfamiliar with the drug is to prescribe twice-daily non-drowsy antihistamines proactively for the first 6-8 weeks, as the rash is difficult to manage once it appears.

The significant stomatitis (mouth sores) associated with the ADC Dato-DXD requires proactive management. Beyond standard steroid rinses and ice chips, a new refrigerated 'chemo mouthpiece' device is being adopted in clinical practice as an innovative, non-pharmacologic tool to prevent this severe side effect.

Data from the SOLAR-1 trial showed that adding prophylactic antihistamines for patients taking alpelisib cut the incidence of all-grade rash in half and reduced high-grade rash by 40%. This has become a standard practice for mitigating dermatologic toxicity with this class of drugs.

Drawing from experience in breast cancer, oncologists advocate for proactive management of the ADC Dato-DXd's side effects. Specifically, they recommend prophylactic corticosteroid mouthwash and ice chips during infusion to prevent or mitigate mucositis, which can severely impact a patient's quality of life.

The perception that pills are less intense than infusions is a misconception. Patients on oral PARP inhibitors require constant monitoring for side effects like fatigue, nausea, and hematologic toxicities, especially in the first three months.